Bombesin (Bn) receptor subtype 3 (BRS-3) is an orphan receptor that is a predicted member of the heptahelical G-protein receptor family and so named because it shares a 50% amino acid homology with receptors for the mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide. In a recent targeted disruption study, in which BRS-3-deficient mice were generated, the mice developed obesity, diabetes, and hypertension. To date, BRS-3's natural ligand remains unknown, its pharmacology unclear, and cellular basis of action undetermined. Furthermore, there are few tissues or cell lines found that express sufficient levels of BRS-3 protein for study. The mammalian bombesin (Bn) 1 -like peptides gastrin-releasing peptide (GRP) and neuromedin B (NMB) contribute to diverse biological functions in the central nervous system (1, 2) and peripheral tissues (1, 2), which include thermoregulation (3), satiety (4), control of circadian rhythm (5), stimulation of pancreatic secretion (6), stimulation of gastrointestinal hormone release (7-9), and macrophage activation (10). These peptides also have important developmental effects (11, 12) and potent growth effects (13-15), causing proliferation of normal cells (13, 14, 16, 17) and various tumor cell lines (15, 16, 18 -20). To date, two mammalian receptor subtypes and their ligands have been identified, each of which has an architecture suggesting they are members of the heptahelical G-protein coupled receptor superfamily (21-23). One subtype, the GRP receptor, exhibits selectivity for GRP (21, 22, 24 -26), whereas the other, the NMB receptor, has selectivity for NMB (23, 26, 27) . The intracellular signaling pathways of these two receptors have been characterized, with ligand binding resulting in stimulation of phospholipase C (14, 28 -30), protein kinase C activation (14), [Ca 2ϩ ] i mobilization (14, 29, 30) , and tyrosine phosphorylation of various intracellular proteins (31-34).
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The mammalian bombesin (Bn) 1 -like peptides gastrin-releasing peptide (GRP) and neuromedin B (NMB) contribute to diverse biological functions in the central nervous system (1, 2) and peripheral tissues (1, 2) , which include thermoregulation (3), satiety (4), control of circadian rhythm (5) , stimulation of pancreatic secretion (6) , stimulation of gastrointestinal hormone release (7) (8) (9) , and macrophage activation (10) . These peptides also have important developmental effects (11, 12) and potent growth effects (13) (14) (15) , causing proliferation of normal cells (13, 14, 16, 17) and various tumor cell lines (15, 16, 18 -20) . To date, two mammalian receptor subtypes and their ligands have been identified, each of which has an architecture suggesting they are members of the heptahelical G-protein coupled receptor superfamily (21) (22) (23) . One subtype, the GRP receptor, exhibits selectivity for GRP (21, 22, 24 -26) , whereas the other, the NMB receptor, has selectivity for NMB (23, 26, 27) . The intracellular signaling pathways of these two receptors have been characterized, with ligand binding resulting in stimulation of phospholipase C (14, 28 -30) , protein kinase C activation (14) , [Ca 2ϩ ] i mobilization (14, 29, 30) , and tyrosine phosphorylation of various intracellular proteins (31) (32) (33) (34) .
Recently, it has been proposed that an orphan receptor may represent a third type of mammalian bombesin receptor (35, 36) . This 399-amino acid protein, which was later identified in human tissues (35) , was named bombesin receptor subtype-3 (BRS-3), due to its 51% and 47% amino acid sequence homology to the GRP receptor and the NMB receptor, respectively. As opposed to GRP receptors and NMB receptors, which have widespread distribution in the central nervous system and peripheral tissues (1, 37, 38) , BRS-3 has a pattern of expression limited to secondary spermatocytes (35) , pregnant uterus (36) , a few brain regions (36) , and human lung (35) , breast (39) , and epidermal cancer cell lines (39) . In a recent study in which BRS-3-deficient mice were generated by targeted disruption, the mice were obese, developed hypertension, and had diabetes, suggesting the BRS-3 receptor is required for regulation of glucose metabolism, energy balance, and maintenance of blood pressure (40) . To date, the natural ligand for BRS-3 is undiscovered, and its intracellular signaling mechanisms are largely unknown. This uncertainty has occurred because no cells have been identified that natively express sufficient numbers of BRS-3 receptors to allow study of intracellular coupling, and no high affinity ligands have been discovered for this receptor. It is known, however, that when the BRS-3 receptor was expressed in Xenopus oocytes (35) or transfected into BALB 3T3 fibroblasts (41) , high concentrations of various natural (35, 36) or synthetic bombesin analogues (41) could promote changes in intracellular calcium.
To overcome these problems, we have recently used two different strategies to create two different cell lines stably expressing this receptor. These cell lines were used to screen various bombesin peptides for their ability to activate phospholipase C and a synthetic analogue of bombesin, [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn- (6) (7) (8) (9) (10) (11) (12) (13) (14) , was identified which has high affinity for the BRS-3 receptor (42) . Using an analogue of this peptide that could be radiolabeled, [D-Tyr ]Bn-(6-14) (42) . The purpose of the present study was to examine the intracellular signaling mechanisms of the BRS-3 receptor using the high affinity ligand [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14), which is an agonist.
MATERIALS AND METHODS
NCI-H1299 cells were a gift from Herb Oie of the National Cancer Institute-Navy Medical Oncology Branch, Naval Medical Center, Bethesda, MD. BALB 3T3 cells were obtained from ATCC, Rockville, MD; Dulbecco's minimum essential medium (DMEM), RPMI 1640, Dulbecco's phosphate-buffered saline (PBS), fetal bovine serum (FBS), G418 sulfate, 12-O-tetradecanoylphorbol-13-acetate (TPA), and Tris/HCl were from Life Technologies, Inc.; formic acid, ammonium formate, disodium tetraborate, EDTA, EGTA, and soybean trypsin inhibitor were from Sigma; phenylmethylsulfonyl fluoride was from Fluka, Ronkonkoma, NY; bovine serum albumin (BSA) fraction V was from ICN Biomedicals Inc., Aurora, OH; aprotinin and HEPES were from Boehringer Mannheim; AG 1-X8 resin, thapsigargin, and GF109203X were from Bio-Rad; monobasic sodium phosphate was from Mallinckrodt; myo- [ 6 ]Bn-(6 -13) methyl ester was also prepared with Leu-O-polystyrene, and free peptide ester was removed from the resin by transesterification with 10% triethylamine/ methanol at 40°C for 48 h. The peptides were first purified on a Sephadex G-25 column (2.5 ϫ 90 cm) followed by preparative high performance liquid chromatography on a Vydac C 18 column (1.5 ϫ 50 cm, 10 -15-m bore size) (45) (46) (47) . After rechromatography to achieve Ն97% purity, the peptides were characterized by amino acid analysis and matrix-assisted laser desorption mass spectroscopy (Finnegan, Hemel Hemstead, United Kingdom).
Preparation and Maintenance of Transfected Cells-NCI-H1299 cells expressing stably transfected hBRS-3 were obtained using LipofectAMINE (Life Technologies, Inc.) to introduce human BRS-3 cDNA containing an NH 2 -terminal flag epitope tag (5Ј-GACTACAAGGAC-GACGATGACAAG-3Ј) subcloned into the expression vectors pCD2 and pcDNA3 as described previously (42) . hBRS-3-transfected BALB 3T3 fibroblasts were transfected using the calcium phosphate precipitation method (48) as described previously (42) . Both wild-type BALB 3T3 cells and NCI-H1299 cell lines were grown in DMEM and RPMI 1640 respectively, supplemented with 10% FBS. The transfected cells were grown in their respective propagation media supplemented with 300 g/ml G418 sulfate. All cell lines were incubated at 37°C in a 5% CO 2 atmosphere. 3 were eluted off Dowex AG-1-X8 anion exchange columns as described previously (50) .
Measurement of Inositol Phosphates (IP)-Cells
In the experiments where total [ 3 H]IP was measured, total [ 3 H]IP was eluted with 2 ml of 1 mM ammonium formate and 100 mM formic acid as described previously (30, 51) . Each of the eluates was collected and mixed with 10 ml of Hydrofluor scintillation mixture (National Diagnostics, Atlanta, GA), and the radioactivity was measured in a scintillation counter.
Intracellular Calcium ([Ca 2ϩ ] i )-Cells harvested by scraping were resuspended in an assay buffer (24.5 mM HEPES (pH 7.4), 98 mM sodium chloride, 6 mM potassium chloride, 2.5 mM monobasic sodium phosphate, 5 mM sodium pyruvate, 5 mM sodium fumarate, 5 mM sodium glutamate, 2 mM glutamine, 11.5 mM glucose, 1.45 mM calcium chloride, 1.15 M magnesium chloride, 0.01% soybean trypsin inhibitor, 0.2% (v/v) amino acid mixture, and 0.2% BSA) to a concentration of 5 ϫ 10 6 cells/ml and incubated with 2 M Fura-2/AM (Molecular Probes, Eugene, OR) for 30 min at 37°C. After washing two times with assay buffer, 2 ml of cell suspension were placed in a Delta PTI Scan 1 spectrofluorimeter (Photon Technology International, South Brunswick, NJ) equipped with a stir bar and water bath (37°C). Fluorescence was measured at dual excitation wavelengths of 340 nm and 380 nm using an emission wavelength of 510 nm. The calcium concentration was calculated using the method of Grynkiewicz et al. (52) .
Immunoprecipitation of Tyrosine-phosphorylated Proteins-Quiescent and confluent hBRS-3-transfected BALB 3T3 cells and NCI-H1299 cells grown on 100-mm culture dishes were preincubated twice with DMEM for 1 h, treated with the indicated concentrations of [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn- (6 -14) or GRP for 10 min at 37°C, and lysed at 4°C in 1 ml of lysing buffer containing 50 mM Tris/HCl (pH 7.5), 150 mM sodium chloride, 1% Triton X-100, 1% deoxycholate, 0.1% (w/v) sodium azide, 1 mM EGTA, 0.4 mM EDTA, 2.5 g/ml aprotinin, 2.5 g/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 0.2 mM sodium vanadate. After centrifugation (15,000 ϫ g, 15 min) and adjustment to a protein concentration of 0.5 mg/ml (Bio-Rad protein assay), the supernatants were immunoprecipitated with 4 g of anti-phosphotyrosine mAb PY20, 4 g of goat anti-mouse IgG, and 30 l of protein A-agarose (Upstate Biotechnology, Inc., Lake Placid, NY) overnight at 4°C. The immunoprecipitates were washed three times with PBS and further analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting.
Western blotting and Measurement of p125 FAK Tyrosine Phosphorylation-Briefly, p125
FAK tyrosine phosphorylation was determined as described recently (53) . Immunoprecipitates were separated by SDSpolyacrylamide gel electrophoresis, and the proteins were electrophoretically transferred to nitrocellulose membranes. After blocking overnight at 4°C in a blocking solution (50 mM Tris/HCl (pH 8.0), 2 mM calcium chloride, 80 mM sodium chloride, 5% non-fat dry milk, 0.05% Tween 20, and 0.02% sodium azide), the membranes were incubated with anti-p125 FAK mAb (1:1000 in blocking solution) for 2 h at 25°C. After washing with blotting solution, the membranes were incubated at 25°C with horseradish peroxidase-conjugated secondary antibody (1: 10,000 in blocking solution) for 30 min. Immunoreactive proteins were detected using the ECL detection system (Pierce). Quantitation of p125 FAK tyrosine phosphorylation was obtained by scanning densitometry (Molecular Devices, Sunnyvale, CA).
Statistical Analysis-Data plotting and iterative curve-fitting was performed with KaleidaGraph graphing software (Synergy Software, Reading, PA). Analysis of Schild plots (54) and statistical analysis of the data were performed using Statview version 1.01 (BrainPower, Inc., Calabasas, CA). Student's t test was used to determine the statistical significance between group means.
Determination of Changes in Cyclic AMP-Quiescent and confluent hBRS-3-transfected BALB 3T3 cells or NCI-H1299 cells grown on 24-well plates were incubated with 500 l of their respective media (DMEM or RPMI 1640), which was supplemented with 2% FBS (v/v) and 2 Ci/ml [ 3 H]adenine for 24 h at 37°C. The medium was removed, replaced with an equivalent volume of serum-free medium, and allowed to incubate for 15 min at 37°C. The medium was removed and replaced with an equivalent volume of serum-free medium containing 1% BSA (w/v), 0.5 mM isobutylmethylxanthine, and the indicated agents at their indicated concentrations. The reactions were terminated by the addition of 100 l of stopping solution (2% SDS (v/v), 5 mM cAMP) followed by 900 l of ice-cold Tris (50 mM, pH 7.4). Samples were stored at Ϫ20°C until analyzed.
Determination of the amount of cAMP formation was obtained using a modified protocol described by Salomon et al. (55) . Frozen samples of hBRS-3-transfected BALB 3T3 cells or NCI-H1299 cells were thawed and added to glass columns containing 1 ml of l:1 (v/v) slurry of Dowex AG1-X8 anion exchange resin, which had been washed once with 4 ml of 1 N sodium hydroxide, once with 4 ml of 1 N hydrochloric acid, and twice with 10 ml of deionized water. The columns were washed with 1 ml of deionized water after addition of sample and stacked over another set of glass columns containing 1 g of alumina, which had been previously washed with 10 ml of deionized water and 4 ml of 100 mM imidazole (pH 7.2). The samples were eluted with 3 ml onto the alumina columns. As a final elution step, 4 ml of 0.1 M imidazole was added to each alumina column. The eluate was collected and mixed with Hydrofluor scintillation fluid, and the radioactivity was counted.
RESULTS
We first examined the effect of [D-Phe 6 ,␤-Ala 11 , Phe 13 (Table I ). This result is consistent with previous studies, which demonstrate that these cells possess a low density of hGRP and hNMB receptors (35) . The hBRS-3-transfected NCI-H1299 cells exhibited a more robust response to [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) at 10 nM and with each of the three peptides at 1000 nM. The untransfected BALB 3T3 cells, which do not possess Bn receptors, failed to respond to any of these peptides (Table I) Table I) .
The results in Table I indicated that in NCI-H1299 cells, but not in BALB 3T3 cells, there were low levels of native Bn receptors (GRP receptor, NMB receptor, or both) that could be stimulated to cause detectable increases in [ (Fig. 2) . In the transfected BALB 3T3 cells, Bn, GRP, and NMB caused no stimulation until concentrations Ͼ100 nM in hBRS-3-transfected BALB 3T3 cells and until concentrations Ͼ10 nM in transfected NCI-H1299 cells (Fig. 2) . We examined six other natural Bn-related peptides for agonist activity, and as shown in Table II , none of these peptides caused a detectable response with concentrations less than 300 nM. Three synthetic peptides reported to have agonist properties against BRS-3 (41) were also evaluated. Two of these, AcNMB-(3-10) and ]Bn-(6 -13) propylamide, stimulated [ 3 H]IP accumulation in a concentration-dependent manner, causing a detectable effect at 219 Ϯ 63 and 892 Ϯ 71 nM (Table II) and causing a half-maximal effect at 333 Ϯ 81 nM and 1924 Ϯ 146 nM, respectively (Fig. 3) . The efficacy of AcNMB-(3-10), however, was only 80% of that seen with [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) (Fig. 3) . (6 -14) by Ն50%, with D-Nal,Cys,Tyr,DTrp,Lys,Val,Cys,Nal-NH 2 being the most potent (Fig. 4) . The inhibition caused by the substance P analogues and D-Nal,Cys,Tyr,D-Trp,Lys,Val,Cys,Nal-NH 2 was examined in detail and found to be concentration-dependent (Fig. 4) . Of these three, D-Nal,Cys,Tyr,D-Trp,Lys,Val,Cys,Nal-NH 2 exhibited the highest potency with half-maximal inhibition at 1. (Fig. 6 ). The kinetics of [Ca 2ϩ ] i release were similar in both transfected cell lines, reaching maximal levels in 10 s (Fig.  6) (Fig. 6, left panel) and attenuated the response in the transfected NCI-H1299 cells by 23% (Fig. 6, middle panel) , the magnitude of the response was reduced only by 15% and the return to basal levels was more rapid than that seen in Ca 2ϩ -containing buffer (Fig. 7) . Recent studies have demonstrated that a number of neuropeptides, without intrinsic tyrosine kinase activity, can stimulate tyrosine phosphorylation of a number of proteins including the cytosolic focal adhesion kinase (p125 FAK ) (32, 33, 59 -63) . Therefore, we studied the effect of [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) on tyrosine phosphorylation of p125 FAK . In both the hBRS-3-transfected BALB 3T3 cells (Fig.  8 ) and the hBRS-3-transfected NCI-H1299 cells (Fig. 9) (Fig. 8) . Furthermore, in these cells, GRP failed to stimulate p125 FAK phosphorylation (Fig. 8) FAK phosphorylation to the same extent (Fig. 9) . In the (Fig. 9) . The phosphorylation induced by [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) was concentration-dependent in both hBRS-3-transfected NCI-H1299 cells and hBRS-3-transfected BALB cells (Fig. 10) for hBRS-3-transfected BALB 3T3 and NCI-H1299 cells were 0.7 Ϯ 0.2 nM and 0.2 Ϯ 0.1 nM, respectively.
To explore the relationship between the ability of hBRS-3 receptor activation to stimulate phospholipase C activity resulting in protein kinase C (PKC) activation and changes in [Ca 2ϩ ] i and its ability to stimulate changes in p125 FAK phosphorylation, we examined the effect of the selective PKC inhibitor GF109203X (64) (Fig. 11) . Furthermore, the combination of GF109203X and thapsigargin had had no effect on phosphorylation alone and had no significant effect on tyrosine phosphorylation of p125 FAK induced by hBRS-3 receptor activation (Fig. 11 ). Since it had been shown previously (66, 67) -14) , bombesin, dopamine, nor neuropeptide Y at concentrations of 3 M were able to inhibit the elevation of cAMP seen with forskolin, although 3 M serotonin caused a significant decrease in cAMP (Table IV) . DISCUSSION Although the BRS-3 receptor was identified several years ago in human (35) and guinea pig (36) , a lack of cell lines expressing physiologically relevant levels of this protein, as well as a lack of a ligand, have impeded studies of the biological role of BRS-3 receptors. To gain further insight into the pharmacology of BRS-3 receptors, we created two cell lines whose signaling sequelae and receptor coupling might resemble those seen in cells expressing native, functional BRS-3 receptors. We chose BALB 3T3 fibroblasts as one candidate, because these cells are devoid of receptors for bombesin-related peptides (24, 49) . Furthermore, both GRP receptors and NMB receptors have been successfully transfected into this cell line, and exhibit intracellular signaling and a pharmacology similar to cells containing native mGRP, hGRP, hNMB, and rNMB receptors (24, 30, 49) . However, it is unknown whether hBRS-3-transfected, murine BALB 3T3 cells have a signaling repertoire identical to human cells natively expressing BRS-3 receptors. Therefore, we included the human non-small cell lung cancer cell line NCI-H1299 in our study, which natively expresses low levels of hBRS-3 receptor (68, 69) , assuming that the necessary elements for hBRS-3 receptor coupling and intracellular signaling were likely extant.
Our results show that, in hBRS- 14 ]Bn-(6 -14) stimulated a rapid rise of cytosolic calcium in both hBRS-3 transfectants under conditions where no change was seen in untransfected cells. Fourth, hBRS-3 receptor-activated increases in cytosolic calcium were only minimally inhibited by removal of extracellular calcium, demonstrating release was primarily from an IP 3 -sensitive intracellular calcium pool. The ability of BRS-3 activation to alter cytosolic calcium is consistent with previous findings with the BRS-3 receptor (35, 41) . When the hBRS-3 receptor was expressed in Xenopus oocytes by injecting hBRS-3 sense mRNA (35) , the hBRS-3 receptor coupled to calcium-activated chloride channels, because high concentrations of GRP or NMB (10 M) caused changes in chloride current. In contrast, uninjected oocytes, or those injected with hBRS-3 receptor antisense mRNA, showed no changes with these peptides. Furthermore, in an earlier study, when hBRS-3 was transfected into BALB 3T3 cells (41) , some GRP-and NMB-related peptides caused changes in cytosolic calcium at high concentrations.
Our studies demonstrate that like a number of other neuropeptide receptors (32, 33, 60 -63) , the hBRS-3 receptor can also stimulate tyrosine phosphorylation of the cytosolic focal adhesion kinase (p125 FAK ), which in a number of cells, has been shown to be required for the promotion of focal adhesions which are important in cell growth and motility (70, 71 FAK tyrosine phosphorylation under conditions in which the activation of GRP receptors was completely inhibited, in hBRS-3-transfected NCI-H1299 cells. This is an important control because recent studies demonstrate that agonist activation of the GRP receptor as well as the NMB receptor cause rapid phosphorylation of both p125 Recent studies show that for some G protein-coupled receptors such as those for angiotensin II (72, 73) , cholecystokinin (74) , epinephrine (75) , bradykinin (33) , and endothelin-1 (73, 76), but not for others such as those for GRP (71) or NMB (31), depletion of Ca 2ϩ or inhibition of PKC activity resulted in a reduction of p125 FAK tyrosine phosphorylation in the presence of agonist. These results demonstrate that, with some G protein-coupled receptors, but not others, activation of the phospholipase C cascade is required for stimulation of tyrosine phosphorylation of p125 FAK . Furthermore, p125 FAK has a PKC phosphorylation sequence (77) , and activation of PKC by phorbol ester or diacylglycerol has been shown to stimulate p125 FAK tyrosine phosphorylation (71) . A number of our findings support the conclusion that, with hBRS-3 receptor activation, the stimulation of tyrosine phosphorylation of p125 FAK is independent of PKC activation and changes in cytosolic calcium. First, the PKC inhibitor GF109203X had no inhibitory effect on [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14)-stimulated p125 FAK tyrosine phosphorylation under conditions where it completely inhibited TPA-stimulated increases. Second, complete inhibition of the ability of hBRS-3 activation to increase [Ca 2ϩ ] i by depletion of intracellular calcium by thapsigargin failed to attenuate hBRS-3 receptor-mediated p125 
p125
FAK tyrosine phosphorylation upon hBRS-3 receptor activation because the combination of GF109203X, at a concentration that blocked TPA-induced p125 FAK tyrosine phosphorylation and thapsigargin at a concentration that inhibited [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14)-induced increases in cytosolic calcium, had no effect on hBRS-3 receptor activation of p125 FAK tyrosine phosphorylation. Therefore, stimulation of tyrosine phosphorylation of p125 FAK by hBRS-3 receptor activation is not altered by simultaneous activation of both limbs of the phospholipase C cascade, which is similar to that described for NMB receptors (53), but not for other receptors such as for thrombin in platelets (75) or CCK A receptors in pancreatic acini (74) .
A number of G protein receptors are coupled to both phospholipase C (81-84) and adenylate cyclase, either through G s or G i . Elevation of cAMP has been associated with activation of the hBRS-3-related receptor, the GRP receptor in Swiss 3T3 cells (66, 67), but not with activation of NMB receptors (29, 30) . In the present study, activation of hBRS-3 receptors in hBRS-3-transfected H1299 cells did not result in stimulation of increases in cAMP. Because PACAP-27 and PACAP-38 were capable of stimulating an increase in cAMP, it is unlikely that the NCI-H1299 cells possessed inadequate G s . Therefore, the failure of hBRS-3 receptors to mediate adenylate cyclase activity in these cells cannot be explained on the basis of insufficient G s availability. In addition, forskolin stimulated a significant cAMP response in the hBRS-3-transfected NCI-H1299 cell line, demonstrating that adenylate cyclase could be directly activated. The possibility that hBRS-3 receptor activation could inhibit cAMP by coupling to G i is also unlikely because [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn-(6 -14) was incapable of inhibiting adenylate cyclase activation by forskolin in the hBRS-3-transfected BALB 3T3 cells. These latter results support the conclusion the hBRS-3, in contrast to the closely related GRP receptor, does not stimulate changes in cyclic AMP as a transduction cascade.
Based on its 51% amino acid identity to the GRP receptor and 47% amino acid identity with the NMB receptor (35) , it was proposed that BRS-3 might be related to these receptors. The ability of bombesin-related peptides to interact with the hBRS-3 receptor has both similarities and differences to what is seen with GRP and NMB receptors. First, it is similar to the GRP and NMB receptors in that it is coupled to phospholipase C activation. In all species examined, including human, rat, and mouse tissues, both the GRP and NMB receptors are coupled to phospholipase C (9, 14, 24, 28 -30, 67) . Second, it resembles both GRP and NMB receptors in its ability to stimulate tyrosine phosphorylation of such proteins as p125 FAK . Third, it demonstrates similar stoichiometric intracellular coupling of these two intracellular pathways to what is seen with the GRP and NMB receptors. With each of these receptors, the dose-response curve for the ability of agonists to stimulate inositol phosphate formation was to the right of its ability to cause tyrosine phosphorylation of p125 FAK (59, 71) . However, the hBRS-3 receptor and the GRP and NMB receptors differ in the stoichiometric relationships of these two dose-responses to each other and to receptor occupation (59, 71, 85) . With each of these three receptors, phospholipase C activation is closely coupled to receptor occupation, whereas submaximal receptor occupation gives maximal p125 FAK tyrosine phosphorylation (9, 53, 71, 86) . These receptor subtypes differ in that the receptor spareness for tyrosine phosphorylation is greater for the hBRS-3 receptor than the GRP or NMB receptor.
The pharmacology of the hBRS-3 receptor, both in terms of its affinity for agonists and many receptor antagonists, has a number of differences from both the GRP receptor and the NMB receptor, as well as the recently described bombesin receptor subtype 4 (BB 4 ) (43) . It differs in that none of the nine naturally occurring peptides that are members of the bombesin family had a potency Ͼ500 nM for activating phospholipase C through the hBRS-3 receptor. In contrast, at least four of these peptides interact in the nanomolar range to activate phospholipase C through the GRP receptor (Bn, GRP, [Phe 13 ]Bn, and litorin) (9, 25) , two peptides with the NMB receptor (NMB, litorin) (9, 25, 29) , and three peptides have nanomolar binding affinities for the BB 4 receptor (Bn, [Phe 13 ]Bn, GRP) (43) . This suggests either its natural ligand is not a bombesin-like peptide, or it has a completely novel sequence differing significantly from the existing naturally occurring bombesin-related peptides. The pharmacology of various synthetic analogues of bombesin and neuromedin B were also found to differ between the hBRS-3 receptor and the known bombesin receptor subtypes. In a previous study (42) ]Bn-(6 -13) propylamide was particularly potent. Our results have both similarities and differences from this study (41) . Our results were similar in that we found each of these three peptides had agonist activity at hBRS-3 receptors. Our results were also similar in the potency of AcNMB-( 13 ]Bn-(6 -13) propylamide, which we found were much lower than they reported (20 -2000 fold), and both peptides were less efficacious than reported previously (41) . The reasons for the discrepancies between the two studies are not clear. In the previous study (41) , because of the potency of NMB analogues, it was proposed that the hBRS-3 receptor had a binding site more like the NMB receptor than the GRP receptor. The finding of a submicromolar agonist potency of AcNMB-(3-10) for hBRS-3, as well as our discovery that DNal,Cys,Tyr,D-Trp,Lys,Val,Cys,Nal-NH 2 , a selective NMB receptor antagonist, also inhibited agonist activity at the hBRS-3 receptor, might be considered to be supportive of this proposal. However, NMB had a low affinity for hBRS-3 in our study, and Six different classes of GRP or NMB receptor antagonists have been described (46, 57, 87, 88) . None of these functioned as a potent receptor antagonist of the hBRS-3 receptor. However, members of three classes of low affinity antagonists for bombesin receptors, ]SP (56, (89) (90) (91) , and a selective NMB receptor antagonist, the somatostatin octapeptide analogue D-Nal,Cys,Tyr,D-Trp,Lys,Val,Cys,Nal-NH 2 (58) , did function as antagonists of the hBRS-3 receptor. The latter somatostatin analogue was the most potent with an affinity of 504 nM, and pharmacological analysis demonstrated it functions as a competitive hBRS-3 receptor antagonist. In a previous study (58) , this analogue was reported to be selective for the NMB receptor and did not interact with the GRP receptor. However, our data demonstrate this compound also functions as a hBRS-3 receptor antagonist with slightly lower affinity than seen with NMB receptors (i.e. 216 nM) (58) . Additional structure-function studies will be needed to determine if somatostatin analogues can be identified which are more selective for hBRS-3 receptors than NMB receptors. Nevertheless, the availability of these three classes of low affinity antagonists will be useful either as starting points to develop more potent antagonists, or in studies of hBRS-3 receptor cell biology aimed at determining its role in various physiological or pharmacological processes.
In conclusion, using the novel ligand [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn- (6 -14) , we demonstrated that hBRS-3 activation stimulates phospholipase C activity and tyrosine kinase activity in a similar manner in two cell lines stably transfected with the hBRS-3 receptor. In contrast to all naturally occurring bombesin-or NMB-related peptides or synthetic analogues tested, only this novel ligand functioned as a high affinity agonist. These results demonstrate that the pharmacology of hBRS-3 is different from any other Bn receptors, and the native ligand likely is not related to any of the naturally occurring Bn peptides currently described. None of the high affinity, selective antagonists for the other Bn receptors interact with the hBRS-3 receptors, although three classes of low affinity antagonists did function as hBRS-3 receptor antagonists. The availability of these hBRS-3-transfected cells, the discovery of the potent agonist [D-Phe 6 ,␤-Ala 11 ,Phe 13 ,Nle 14 ]Bn- (6 -14) , and three classes of low affinity Bn receptor antagonists that also function as hBRS-3 receptor antagonists should prove valuable in the search for the natural ligand for hBRS-3 and in further studies investigating its importance in physiological and pathological processes. 
